Neoadjuvant Immunotherapy Plus Chemotherapy for Potentially Resectable Stage IIIA/IIIB Non-Small Cell Lung Cancer

PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

March 20, 2020

Primary Completion Date

September 6, 2023

Study Completion Date

December 31, 2027

Conditions
IIIA Stage Non-small Cell Lung Cancer
Interventions
DRUG

Sintilimab Injection

"Preoperative:~Sintilimab: 200mg QD, one cycle every 21 days, the first day of each cycle, a total of two cycles.~Albumin paclitaxel: 135mg / m2 QD, 1 cycle every 21 days, 1 day and 8 days of each cycle, 2 cycles in total.~Carboplatin: AUC 5mg QD, one cycle every 21 days, two cycles in total~Postoperative:~Patients began to receive postoperative adjuvant treatment within 21-60 days after the operation. Specific medication plan:~Sintilimab: 200mg QD, one cycle every 21 days, the first day of each cycle, a total of 8 cycles.~Albumin paclitaxel: 135mg / m2 QD, 1 cycle every 21 days, 1 day and 8 days of each cycle, 2 cycles in total.~Carboplatin: AUC 5mg QD, one cycle every 21 days, two cycles in total."

Trial Locations (1)

130000

The First Hospital Of Jilin University, Changchun

All Listed Sponsors
lead

The First Hospital of Jilin University

OTHER

NCT04326153 - Neoadjuvant Immunotherapy Plus Chemotherapy for Potentially Resectable Stage IIIA/IIIB Non-Small Cell Lung Cancer | Biotech Hunter | Biotech Hunter